Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

Study Purpose

This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 1 Year - 65 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Completion of Study 1042-TSC-3001 or participants who continue to meet study requirements in Study 1042-TSC-2001. 2. Participant/parent(s)/LAR(s) willing and able to give written informed consent/assent, after being properly informed of the nature and risks of the study and prior to engaging in any study-related procedures. If the participant is not qualified or able to provide written informed consent based on age, developmental stage, intellectual capacity, or other factors, parent(s)/LAR(s) must provide assent for study participation, if appropriate. 3. Parent(s)/caregiver(s) is (are) willing and able to maintain an accurate and complete daily seizure diary for the duration of the study. 4. Willing and able to take Investigational product (IP) (suspension) as directed with food TID. 5. Women of childbearing potential (WOCBP) must be using a medically acceptable method of birth control and have a negative quantitative serum beta-human chorionic growth hormone (β-HCG) test collected at the initial visit. Childbearing potential is defined as a female who is biologically capable of becoming pregnant. Medically acceptable methods of birth control include intrauterine devices (that have been in place for at least 1 month prior to the screening visit), hormonal contraceptives (eg, combined oral contraceptives, patch, vaginal ring, injectables, and implants), and surgical sterilization (such as oophorectomy or tubal ligation). When used consistently and correctly, "double-barrier" methods of contraception can be used as an effective alternative to highly effective contraception methods. Contraceptive measures such as Plan B™, sold for emergency use after unprotected sex, are not acceptable methods for routine use. 6. Male participants must agree to use highly effective contraceptive methods during the study and for 30 days after the last dose of IP. Highly effective methods of contraception include surgical sterilization (such as a vasectomy) and adequate "double-barrier" methods.

Exclusion Criteria:

1. Pregnant or breastfeeding. 2. An active Central nervous system (CNS) infection, demyelinating disease, or degenerative neurological disease. 3. History of psychogenic nonepileptic seizures. 4. Any disease or condition (other than TSC) at the initial visit that could compromise the hematologic, cardiovascular (including any cardiac conduction defect), pulmonary, renal, gastrointestinal, or hepatic systems; or other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the IP, or would place the participant at increased risk or interfere with the assessment of safety/efficacy. This may include any illness in the past 4 weeks which in the opinion of the investigator may affect seizure frequency. 5. Unwillingness to avoid excessive alcohol use or cannabis use throughout the study. 6. Have active suicidal plan/intent or have had active suicidal thoughts in the past 6 months or a suicide attempt in the past 6 months. 7. Known sensitivity or allergy to any component in the IP(s), progesterone, or other related steroid compounds. 8. Exposed to any other investigational drug (except for GNX in Study 1042-TSC-2001 or Study 1042-TSC-3001) or investigational device within 30 days or fewer than 5 half-lives prior to Visit 1 (first visit of the OLE). For therapies in which half-life cannot be readily established, the Sponsor's medical monitor should be consulted.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05604170
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Marinus Pharmaceuticals
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Enrolling by invitation
Countries Australia, Canada, China, France, Germany, Israel, Italy, Spain, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Tuberous Sclerosis Complex
Arms & Interventions

Arms

Experimental: Ganaxolone (GNX) oral suspension, 3 times a day (TID)

Interventions

Drug: - Ganaxolone

GNX will be administered.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Arkansas Children's Research Institute, Little Rock, Arkansas

Status

Address

Arkansas Children's Research Institute

Little Rock, Arkansas, 72202

Los Angeles, California

Status

Address

UCLA Mattel Children's Hospital, TSC Center

Los Angeles, California, 90095

Children's Hospital of Orange County, Orange, California

Status

Address

Children's Hospital of Orange County

Orange, California, 92868

Children's Hospital Colorado, Aurora, Colorado

Status

Address

Children's Hospital Colorado

Aurora, Colorado, 80045

Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland

Status

Address

Mid-Atlantic Epilepsy and Sleep Center

Bethesda, Maryland, 20817

Mayo Clinic - Rochester, Rochester, Minnesota

Status

Address

Mayo Clinic - Rochester

Rochester, Minnesota, 55905

University of Rochester Medical Center, Rochester, New York

Status

Address

University of Rochester Medical Center

Rochester, New York, 14642

Chapel Hill, North Carolina

Status

Address

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599

Atrium Health/Levine Children's Hospital, Charlotte, North Carolina

Status

Address

Atrium Health/Levine Children's Hospital

Charlotte, North Carolina, 28207

Duke University Medical Center, Durham, North Carolina

Status

Address

Duke University Medical Center

Durham, North Carolina, 27712

Penn State Children's Hospital, Hershey, Pennsylvania

Status

Address

Penn State Children's Hospital

Hershey, Pennsylvania, 17033

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Status

Address

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104

Medical University of South Carolina, Charleston, South Carolina

Status

Address

Medical University of South Carolina

Charleston, South Carolina, 29425

Le Bonheur Children's Hospital, Memphis, Tennessee

Status

Address

Le Bonheur Children's Hospital

Memphis, Tennessee, 38103

Austin, Texas

Status

Address

Child Neurology Consultants of Austin (CNCA)

Austin, Texas, 78757

Houston, Texas

Status

Address

McGovern Medical School at the University of Texas Health Science Center

Houston, Texas, 77030

International Sites

Austin Health, Heidelberg, Australia

Status

Address

Austin Health

Heidelberg, , VIC 3084

Alfred Health, Melbourne, Australia

Status

Address

Alfred Health

Melbourne, , VIC 3004

Royal Melbourne Hospital, Parkville, Australia

Status

Address

Royal Melbourne Hospital

Parkville, , VIC 3050

The Royal Children's Hospital Melbourne, Parkville, Australia

Status

Address

The Royal Children's Hospital Melbourne

Parkville, , VIC 3052

Hôtel Dieu de Montréal - CHUM, Montréal, Canada

Status

Address

Hôtel Dieu de Montréal - CHUM

Montréal, , H2X 0C2

CHU Sainte-Justine, Montréal, Canada

Status

Address

CHU Sainte-Justine

Montréal, , H3T 1C5

The Hospital for Sick Children, Toronto, Canada

Status

Address

The Hospital for Sick Children

Toronto, , M5G 1X8

Toronto Western Hospital, Toronto, Canada

Status

Address

Toronto Western Hospital

Toronto, , M5T 2S8

BC Children's Hospital, Vancouver, Canada

Status

Address

BC Children's Hospital

Vancouver, , V6H 3V4

Peking University First Hospital, Beijing, China

Status

Address

Peking University First Hospital

Beijing, , 100034

Beijing, China

Status

Address

Beijing Children Hospital, Capital Medical University

Beijing, , 100045

Chinese PLA General Hospital, Beijing, China

Status

Address

Chinese PLA General Hospital

Beijing, , 100080

Beijing, China

Status

Address

The Affiliated Hospital of Guizhou Medical University

Beijing, , 550004

First Hospital of Jilin University, Jilin, China

Status

Address

First Hospital of Jilin University

Jilin, , 130028

Qingyang, China

Status

Address

Chengdu's Women and Children's Central Hospital

Qingyang, , 610000

University Hospital of Lyon, Bron, France

Status

Address

University Hospital of Lyon

Bron, , 69229

Robert-Debré Hospital, Paris, France

Status

Address

Robert-Debré Hospital

Paris, , 75019

Hôpital de la Pitié-Salpêtrière, Paris, France

Status

Address

Hôpital de la Pitié-Salpêtrière

Paris, , 75651

University Hospital of Rennes, Rennes, France

Status

Address

University Hospital of Rennes

Rennes, , 35700

University of Strasbourg, Strasbourg, France

Status

Address

University of Strasbourg

Strasbourg, , 67084

Bielefeld, Germany

Status

Address

Epilepsie-Zentrum Bethel - Krankenhaus Mara

Bielefeld, , 33617

University Hospital Bonn, Bonn, Germany

Status

Address

University Hospital Bonn

Bonn, , 53127

ZNN - Epilepsiezentrum Frankfurt am Main, Frankfurt, Germany

Status

Address

ZNN - Epilepsiezentrum Frankfurt am Main

Frankfurt, , 60528

Universitäts Krankenhaus Freiburg, Freiburg, Germany

Status

Address

Universitäts Krankenhaus Freiburg

Freiburg, , 79106

Gemeinschaftskrankenhaus Herdecke, Herdecke, Germany

Status

Address

Gemeinschaftskrankenhaus Herdecke

Herdecke, , 58313

Epilepsiezentrum Kleinwachau gGmbH, Radeberg, Germany

Status

Address

Epilepsiezentrum Kleinwachau gGmbH

Radeberg, , 1454

Soroka University Medical Center, Be'er Sheva, Israel

Status

Address

Soroka University Medical Center

Be'er Sheva, , 8410100

Schneider Children´s Medical Center, Petah Tikva, Israel

Status

Address

Schneider Children´s Medical Center

Petah Tikva, , 4920235

Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Status

Address

Tel-Aviv Sourasky Medical Center

Tel Aviv, , 64239

Azienda Ospedaliero-Universitaria Meyer, Firenze, Italy

Status

Address

Azienda Ospedaliero-Universitaria Meyer

Firenze, , 50139

Genova, Italy

Status

Address

Pediatric Neurology and Muscular Diseases Unit - University of Genoa

Genova, , 16147

Policlinico Umberto I, Rome, Italy

Status

Address

Policlinico Umberto I

Rome, , 00185

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Status

Address

Hospital de la Santa Creu i Sant Pau

Barcelona, , 8025

Hospital Universitari Vall d'Hebron, Barcelona, Spain

Status

Address

Hospital Universitari Vall d'Hebron

Barcelona, , 8035

Hospital Sant Joan de Déu, Barcelona, Spain

Status

Address

Hospital Sant Joan de Déu

Barcelona, , 8950

Madrid, Spain

Status

Address

Hospital Infantil Universitario Niño Jesús

Madrid, , 28009

Hospital Ruber International, Madrid, Spain

Status

Address

Hospital Ruber International

Madrid, , 28034

Málaga, Spain

Status

Address

Hospital Regional Universitario de Málaga

Málaga, , 29010

Valencia, Spain

Status

Address

Hospital Universitario y Politécnico La Fe

Valencia, , 46026

Bristol Royal Hospital for Children, Bristol, United Kingdom

Status

Address

Bristol Royal Hospital for Children

Bristol, , BS2 8AE

Oxford, United Kingdom

Status

Address

NHS acute tertiary referral centre, John Radcliffe Hospital

Oxford, , OX3 9DU

Salford Royal Hospital, Salford, United Kingdom

Status

Address

Salford Royal Hospital

Salford, , M6 8HD

Sheffield Children's Hospital, Sheffield, United Kingdom

Status

Address

Sheffield Children's Hospital

Sheffield, , S10 2TH

Stay Informed & Connected